New radioactive tracer aims to spot hidden cancer in lymph nodes

NCT ID NCT04840472

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests a radioactive imaging agent called 111In-panitumumab in 28 people with head and neck cancer. The goal is to see if it can safely and accurately find cancer in lymph nodes compared to the standard dye method used during surgery. The study is currently suspended.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

111In-panitumumab (a radioactive imaging agent)

What this could lead to

If successful, this could lead to a more accurate, less invasive way to detect cancer spread to lymph nodes in head and neck cancer patients.

What could go wrong

This is a very early, small pilot study (Phase 1) that is currently suspended. The imaging agent may not work better than current methods, and there are unknown safety risks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Stanford University

    Stanford, California, 94305, United States